Meningitec preservative free vaccine is intended to treat N. meningitidis, an infectious disease which occurs majority in children, and can lead to meningitis, sepsis and pneumonia.
Nuron Biotech chief executive officer and founder Shankar Musunuri said the acquisition of Meningitec enables the company to expand its infectious disease products portfolio and bring the vaccines to patients with unmet needs.
Nuron Biotech marketing and business development vice president Richard Dinovitz said the company is planning to expand into markets with unvaccinated and under-vaccinated populations, helping address public health needs around the world.
"In the early 2000s, Meningitec played a pioneering role in reducing disease caused by N. meningitidis serogroup C by 93 percent in children in the U.K," Dinovitz added.